MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/24741264251359888

Медицинская библиотека · Journal of vitreoretinal diseases · 2025

Cost-Effectiveness of Treatments for Diabetic Macular Edema: Simulated Bevacizumab-First Step Therapy Versus Real-World Practice.

Leung Ella H, Grewal Dilraj S, Gerbi Emanuel, Busquets Miguel, Niles Philip, Gong Dan A, Kolomeyer Anton M, Aggarwal Nitika, Boucher Nick, Blim Jill, Sanders Reginald, Hahn Paul

СтатьяПеревод пока не подготовлен

Аннотация

Purpose: To compare the incremental cost-effectiveness of a clinical trial-simulated step-therapy versus real-world treatment for diabetic macular edema (DME).

Methods

A theoretical Markov model (follow-up of 2 years and lifetime of 17 years) from the 2025 US societal perspective was used to compare the costs and cost-effectiveness between bevacizumab-first (Protocol AC) and real-world regimens from the Vestrum Health database. The modeling used mean characteristics from a reference case and analyzed low- and high-cost scenarios, total societal costs from formal and informal healthcare and non-healthcare sectors, and differences in utility (visual acuity outcomes) between arms.

Results

Protocol AC bevacizumab-first in the reference case was 14% more expensive at 2 years, with a total adjusted societal cost of $69 850 versus $61 304 for real-world treatment. Although visual acuity gains were higher with Protocol AC, the incremental cost-utility ratio (ICUR) was $105 335/quality-adjusted life years (QALY) at 2 years and $151 032/QALY over 17 years, higher than most societal willingness-to-pay thresholds. In the low-cost scenario, Protocol AC was neither cost-saving nor cost-effective at 2 years (ICUR $82 283/QALY) but was cost-effective over 17 years (ICUR $591/QALY). In the high-cost scenario, Protocol AC was not cost-effective at 2 years (ICUR $219 420/QALY) or 17 years (ICUR $207 589/QALY). Probability sensitivity analysis showed that Protocol AC was more expensive in 87% of modeled scenarios and not cost-effective in 76%.

Conclusions

Compared with real-world treatment, protocol AC bevacizumab-first treatment for DME was generally not cost-saving. Although better vision outcomes were achieved with bevacizumab-first, the protocol was generally not cost-effective due to greater treatment burdens.

Для цитирования: Leung Ella H, Grewal Dilraj S, Gerbi Emanuel, Busquets Miguel, Niles Philip, Gong Dan A, Kolomeyer Anton M, Aggarwal Nitika, Boucher Nick, Blim Jill, Sanders Reginald, Hahn Paul. Cost-Effectiveness of Treatments for Diabetic Macular Edema: Simulated Bevacizumab-First Step Therapy Versus Real-World Practice.. Journal of vitreoretinal diseases. 2025. DOI: 10.1177/24741264251359888.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.